Abstract
AD is a chronic systemic disease, predominantly driven by dysregulated type 2 immunity associated with increased total IgE levels and sensitization to various common allergens. We report the change in total and allergen-specific IgE serum levels in adolescents (aged 12–17 years) with moderate-to-severe AD treated with dupilumab in the LIBERTY AD ADOL phase 3 trial (NCT03054428).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
